Ninfa Candela to Ustekinumab
This is a "connection" page, showing publications Ninfa Candela has written about Ustekinumab.
Connection Strength
0.590
-
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
Score: 0.241
-
Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Guerin A, Fan T. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States. Curr Med Res Opin. 2024 05; 40(5):877-885.
Score: 0.234
-
Cleveland NK, Ghosh S, Kathe N, Umashankar K, Mirchandani K, Hait A, Paul R, Candela N, Fan T, Rubin DT. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
Score: 0.061
-
Vu M, Ghosh S, Umashankar K, Weber L, Landis C, Candela N, Chastek B. Comparison of surgery rates in biologic-na?ve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN. BMC Gastroenterol. 2023 Mar 25; 23(1):87.
Score: 0.054